



PANCREATIC ISLET CELL GROWTH FACTORS

FIELD OF THE INVENTION

- 5 The present invention relates generally to growth factors and more particularly to growth factors which are capable of stimulating or otherwise facilitating formation of insulin-secreting cells. The identification of these growth factors permits the development of protocols to culture cells *in vitro* for transplantation into mammalian and in particular human subjects with insulin-dependent type 1 diabetes or related conditions. It is further
- 10 contemplated that the endogenous expression of growth factors required for the development of insulin-producing cells may be manipulated *in vivo*, by the appropriate administration of agents including genetic agents capable of regulating the expression of growth factors in pancreatic duct epithelial cells. The growth factors may also be administered to subjects with type 1 diabetes to stimulate the proliferation and
- 15 differentiation of pancreatic cells into insulin-secreting cells. The present invention also provides modulators of growth factor-mediated pancreatic cell differentiation. Such modulators are useful in the treatment *inter alia* of β cell tumors and/or pancreatic cancer.

BACKGROUND OF THE INVENTION

- 20 Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in Australia or any other country.
- 25 Bibliographic details of the publications referred to by author in this specification are collected at the end of the description.

- Insulin-dependent type 1 diabetes is caused by lack of insulin, due to autoimmune-mediated destruction of pancreatic islet cells. People with type 1 diabetes need regular
- 30 insulin injections to control their blood glucose level, a matter of life or death. Pancreas transplantation is currently the only curative therapy for type 1 diabetes, but it is hampered

by the requirement for potentially toxic, life-long immunosuppressive drugs and by the dearth of human donors. These barriers could be overcome by discovery of growth factors to (re)generate cells.

- 5 The factors and mechanisms which regulate lineage differentiation of islet cells from multi-potent precursors are poorly understood. Broadly speaking, two classes of co-operative signals guide cellular proliferation, differentiation and apoptosis: soluble signals including hormones and growth factors and insoluble signals delivered by extracellular matrix (ECM) proteins (Lelievre *et al.*, 1996). Classical hormones play important roles in
10 regulating endocrine cell development. For example, pituitary luteinizing hormone (LH) controls lineage differentiation of Leydig cells in the testis and of granulosa cells in the ovary, while thyroid stimulating hormone (TSH) and adrenocortico trophic hormone (ACTH) maintain differentiation of thyroid follicular cells and adrenocortical cells, respectively. Islet cell development seems to be an exception, as no hormonal control has
15 been demonstrated.

- The mammalian pancreatic primordia evaginate from foregut endoderm in early fetal life. The adult pancreas consists of two distinct tissue types: endocrine tissue, the islets of Langerhans, which secretes hormones into the bloodstream, and exocrine tissue, which
20 secretes digestive enzymes into the intestinal tract. The islets contain four main types of endocrine cells that synthesize insulin, glucagon, somatostatin and pancreatic polypeptide. These hormones, notably insulin, play critical roles in glucose metabolism and homeostasis. All four types of endocrine cells are believed to arise from common multi-potent precursors which express the PDX-1 (also called IPF-1, STF-1 and IDX-1)
25 transcription factor and co-express several hormones and neuronal markers as they begin to differentiate (Slack, 1995). Several soluble extracellular factors have been implicated in pancreatic epithelial cell development, including members of the TGF- β 1 superfamily of transforming growth factors. Transgenic mice expressing a dominant negative TGF- β receptor II controlled by the mouse metallothionein 1 promoter display increased
30 proliferation and impaired differentiation of pancreatic acinar cells (Bottinger *et al.*, 1997). Transgenic mice expressing a dominant negative activin receptor controlled by the human

- insulin promoter have hypoplasia of pancreatic islets (Yamaoka *et al.*, 1998). Hebrok *et al.* (1998) found that Activin B is expressed in the notochord adjacent to the domain of foregut endoderm from which the pancreatic primordia derives. Activin B represses endodermal expression of sonic hedgehog, a prerequisite for expression of the
- 5 homeodomain transcription factor, PDX-1, required for pancreatic development (Jonsson *et al.*, 1994; Offield *et al.*, 1996). The bone morphogenetics (BMPs), members of the TGF- β superfamily, have been shown to be important in development of kidney tubule, lung and other organ epithelia (Hogan, B.L, 1996; Weaver *et al.*, 1999) and are expressed in the pancreas. BMP 7 was detected immunocytochemically in human fetal pancreas duct
- 10 epithelium (Vukicevic *et al.*, 1994) and by mRNA *in situ* hybridization in mouse pancreas epithelium between E12.5 and E14.5 (Lyons *et al.*, 1995). The appropriate and timely expression of these factors contributes to the appropriate embryonic development of the pancreas.
- 15 Laminin-1 is a heterotrimeric cellular matrix glycoprotein (Mr=850,000) composed of (400 kDa), (210 kDa) and (200 kDa) disulfide-bonded chains (Ekblom, 1996). Laminin-1 has been shown to induce specifically β -casein gene expression in mammary epithelia (Streuli *et al.*, 1995) and neuron generation from retinal neuroepithelial cells (Frade *et al.*, 1996). The cross region of laminin-1 selectively promotes fetal lung epithelial cell proliferation,
- 20 the outer globular region of the α 1 and β 1 chains mediates epithelial cell polarization, and the inner globular region of the β 1 chain binds to heparin sulfate proteoglycan and stimulates lumen formation (Schuger *et al.*, 1996). There are at least two types of laminin-1 receptor: the α_6 integrins and the non-integrin α -dystroglycan (α DG) (Ekblom, 1996). Integrins are a well-characterized family of heterodimeric cell adhesion molecules
- 25 composed of non-covalently bound (120-180 kDa) and (90-110 kDa) subunits. α DG is a 156 kDa extracellular peripheral membrane glycoprotein associating with a transmembrane glycoprotein, which binds laminin-1 with high affinity but does not bind nidogen, fibronectin or collagen IV (Ekblom, 1996). The present inventors have found by RT-PCR that mRNAs for α_6 integrin and α DG are expressed in the developing mouse pancreas from
- 30 at least 13.5 dpc and α_6 integrin protein is detected by immunofluorescence from at least 15.5 dpc.

0978494-024504

Coincident with these laminin-1 studies, the present inventors also carried out a representational difference analysis (RDA) in which genes expressed in normal human pancreas were subtracted from genes expressed in pancreas from a child with diffuse islet cell hyperplasia (nesidioblastosis). One of the genes found to be differentially expressed in nesidioblastosis was bone morphogenetic protein (BMP) 7. BMPs were originally identified as proteins that induce bone and cartilage formation in ectopic extraskeletal sites *in vivo* (Wozney, 1989). *In vitro* studies have revealed that BMPs have multiple effects on various cells types. BMP-2 deficient mice have amnion/chorion malformation and defective cardiac development, and die between 7.5-9 dpc (Zhang and Bradley, 1996). BMP 4 deficient mice have defects in extra-embryonic and posterior/ventral mesoderm formation and die between 6.5-9.5 dpc (Winnier *et al.*, 1995). BMP 7 deficient mice have defects in kidneys and eyes and die shortly after birth (Dudley *et al.*, 1995; Luo *et al.*, 1995).

In work leading up to the present invention, the inventors developed a low cell density, serum-free culture system for dissociated pancreatic cells from 13.5 day-postcoitum (dpc) mouse fetuses and investigated the effects of four major ECM proteins, collagens I and IV, fibronectin and laminin-1, on the differentiation of fetal pancreatic cells into islet cells (Jiang *et al.*, 1999). Following four days of culture in complete HYBRIDOMA medium, the total cell number decreased to one-third of that plated, but the number of insulin-positive cells increased 10-fold. Both collagens I and IV inhibited (by over 50%) the survival of pancreatic cells compared to medium alone, whereas fibronectin had no effect. However, in the presence of soluble laminin-1, the number of cells increased linearly by 60-fold. Laminin-1 was also shown to be expressed in the epithelial basement membrane of the 13.5-17.5 day fetal pancreas (Jiang *et al.*, 1999). These results provided the first evidence that laminin-1 plays an important role in promoting differentiation of pancreatic cells. The present inventors have further developed an *in vivo* culture system in which the interaction of laminin-1 with particular BMPs has a synergistic effect which result in an increased frequency in the formation of cystic epithelial colonies that contain insulin-producing cells. The subject inventors showed that they are able to regulate the

- 5 -

development and formation of cystic epithelial colonies which contain cells that express insulin by modulating the quantity of particular BMPs and/or laminin-1. The present inventors further identified that TGF β 1 and Activin A antagonize the activity of particular BMPs. Thus, the present inventors are now able to regulate the development of insulin-producing β -cells from pancreatic epithelial cells *in vitro*. The present invention further permits the development of protocols for treating diabetes as well as conditions such as β cell hyperplasia, nesidioblastosis and pancreatic cancer.

FOIA b 7 - DATED 11/03/00

SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the
5 inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Nucleotide and amino acid sequences are referred to by a sequence identifier, i.e. <400>1, <400>2, etc. A sequence listing is provided after the claims.

10

One aspect of the present invention contemplates a method of stimulating or otherwise facilitating formation of colonies of pancreatic cells containing insulin-secreting cells, said method comprising culturing pancreatic cells in the presence of a bone morphogenetic protein (BMP) or a functional derivative, homologue, mimetic, analogue or agonist thereof
15 for a time and under conditions sufficient for colonies to form comprising insulin-secreting cells.

Another aspect of the present invention provides a method of stimulating or otherwise facilitating formation of colonies of pancreatic cells containing insulin-secreting cells, said
20 method comprising culturing pancreatic cells in the presence of laminin-1 or laminin-1-containing extracellular matrix (ECM) or a functional derivative, homologue, mimetic, analogue or agonist thereof for a time and under conditions sufficient for colonies to form comprising insulin-secreting cells.

A further aspect of the present invention provides a method for stimulating or otherwise facilitating formation of colonies of pancreatic cells containing insulin-secreting cells, said method comprising culturing mammalian pancreatic cells in the presence of a BMP or a functional derivative, homologue, mimetic, analogue or agonist thereof and laminin-1 or laminin-1-containing ECM or a functional derivative, homologue, mimetic, analogue or
30 agonist thereof for a time and under conditions sufficient for colonies to form comprising insulin-secreting cells.

0978441-024604
1097844-024604

Still another aspect of the present invention provides a method of stimulating or otherwise facilitating formation of cystic epithelial colonies containing insulin-secreting cells, said method comprising culturing pancreatic cells in the presence of one or both of a BMP or a functional derivative or homologue, mimetic, analogue or agonist thereof and laminin-1 or
5 laminin-1-containing ECM or a functional derivative, homologue, mimetic, analogue or agonist thereof for a time and under conditions sufficient for colonies to form comprising insulin-secreting cells.

10 Yet another aspect of the present invention contemplates a method of stimulating or otherwise facilitating the formation of colonies of pancreatic cells containing insulin-secreting cells, said method comprising culturing pancreatic cells in the presence of a BMP selected from the group consisting of BMP 2, BMP 3, BMP 4, BMP 5, BMP 6 and BMP 7 or any other molecule having BMP properties or functional derivatives or homologues or
15 mimetics or analogues or agonists thereof and laminin-1 or laminin-1-containing ECM or a functional derivative, homologue, mimetic, analogue or agonist thereof under time and conditions sufficient for colonies to form comprising insulin-secreting cells.

Even still another aspect of the present invention provides a method of stimulating or
20 otherwise facilitating formation of colonies containing insulin-secreting cells from pancreatic cells, said method comprising culturing pancreatic cells in the presence of a BMP or a heterodimer formed from two or more BMPs or a functional derivative, homologue, mimetic, analogue or agonist forms thereof for a time and under conditions sufficient for colonies to form comprising insulin-secreting cells.

25

Even yet another aspect of the present invention is directed to a method of stimulating or otherwise facilitating formation of colonies containing insulin-secreting cells from pancreatic cells, said method comprising culturing pancreatic cells in the presence of a BMP or a heterodimer formed from two or more BMPs and laminin-1 or laminin-1-
30 containing ECM or functional derivatives, homologues, mimetics, analogues or agonists thereof for a time and under conditions sufficient for colonies to form comprising insulin-

secreting cells.

Another aspect of the present invention contemplates a method of treating comprising modulating the expression of one or more endogenous genetic sequences encoding a BMP
5 to facilitate the formation of colonies of insulin-secreting cells.

A further aspect of the present invention contemplates a method for the treatment of a subject with type 1 diabetes or a related condition, said method comprising transplanting to said subject, insulin-secreting cells produced following the *in vitro* culture of pancreatic
10 cells in the presence of a BMP or a heterodimer formed from two or more BMs or functional derivatives, homologues, mimetics, analogues or agonists thereof and optionally in the presence of laminin-1 or laminin-1-containing ECM or derivatives, homologues, mimetics, analogues or agonists thereof comprising insulin-secreting cells for at time and under conditions sufficient for colonies to form.

15 Still a further aspect of the present invention provides a method for the treatment or prophylaxis of islet/ β cell hyperplasia adenoma or a related condition including pancreatic cancer, said method comprising administering to a subject an effective amount of an antagonist of a BMP for a time and under conditions sufficient to inhibit the formation or
20 maintenance of insulin-producing β cells.

007544-034604
TOP SECRET

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a schematic representation of BMP expression vectors showing the relative positions of the pro-domains, epitope tag (glu or myc) and the active peptide within the vector pEFBOS. The processing site at which proteolytic cleavage occurs to release the tagged active peptide is indicated. In addition to the vectors shown, other combinations of epitope, tag, pro-domain and active peptide were constructed.

Figure 2 is a photographic representation of Western blot analysis of conditioned media from COS cells transfected with pEFBOS constructs encoding myc tagged BMP 4 (4-myc), glu/glu tagged BMP 6 (6-glu), glu/glu tagged BMP 7 (7-glu) or combinations thereof. Approximately 20 μ l of medium was subjected to SDS-PAGE and the separated sample electrotransferred to filter membrane. The filters were blocked with 0.1% w/v BSA in PBS and incubated with mouse anti-myc or anti-glu/glu antibody. Bound antibody was visualized with peroxidase-conjugated anti-mouse Ig ECL (Amersham) detection kit. The position and size (in kD) of the molecular weight markers is shown on the left of each panel and antibody used for detection shown on the right. The proteins encoded by the constructs used to transfect the COS cells are indicated above.

Figure 3 is a graphical representation of BMP-induced osteoblast transformation (alkaline phosphatase activity) of C2C12 myoblast cells.

Figure 4 is a photographic representation of BMP 6/6 (A) and BMP 7/7 (B) stimulated colony formation of 13.5 dpc fetal mouse pancreas cells cultured for four days in the presence of 200 μ g/ml laminin-1. Cells were stained with polyclonal guinea pig anti-insulin immunoglobulins and visualized by peroxidase-conjugated rabbit anti-guinea pig immunoglobulins. The bottom left panels display many insulin-positive (brown) cells.

Figure 5 is a graphical representation of BMP dose-dependence of colony formation of 13.5 dpc fetal mouse pancreas cells cultured for four days.

Figure 6 is a photographic representation of colonies induced by culture of 13.5 dpc fetal pancreas cells for eight days in the presence of BMP 6/6 or BMP 7/7, and laminin-1. Immunoperoxidase staining (brown) for insulin is evident.

- 5 **Figure 7** is a photographic representation of immunofluorescence staining (yellow) for BrdU incorporated into the nuclei of cells in colonies of fetal mouse pancreas cells induced by BMP 7.

- Figure 8** is a photographic representation showing that BMP 6 (10 ng/ml) synergizes with
10 laminin-1 (160 μ g/ml) to promote cystic colony formation by fetal mouse pancreas epithelial cells. Phase contrast images show dissociated cells cultured for 2 or 6 days in the absence or presence of laminin-1 and BMP 6. By day 2, small colonies and some tubular-like structures (closed arrow) were observed in the presence of BMP 6 in cultures containing laminin-1. At day 6, in the presence of both laminin-1 and BMP 6, colonies
15 were increased in numbers and variable size. Colonies $\leq 30 \mu$ m (open arrow) were excluded from the quantitation of colony numbers in Figure 9 below.

- Figure 9** is a diagrammatic representation showing frequency of colonies (mean + s.d.) as a function of increasing concentrations of BMP 6 or BMP 5 in the presence of 160 μ g/ml
20 of laminin-1. Colonies were directly counted under a phase contrast microscope ($\times 10$). Colonies $\leq 30 \mu$ m (see Figure 8) were not counted.

- Figure 10** is a diagrammatic representation showing the effect of TGF- β superfamily members on BMP 6 induced colonies (mean + s.d.) in the presence of 160 μ g/ml laminin-
25 1. (A) Effect of BMP 6, TGF- β 1 or Activin A (all 100 ng/ml) and laminin-1 alone ("vehicle") on colony numbers. (B) Effect of BMP 5, TGF- β 1 or Activin A (all 100 ng/ml) on BMP 6 (10 ng/ml)-induced colony numbers. (C) Dose-dependent inhibition of TGF- β 1 (square) and Activin A (circle) of BMP 6 (10 ng/ml)-induced colony numbers.

- 30 **Figure 11** is a photographic representation showing fluorescence images of fetal pancreas cell colonies generated by culture for 6 days in the presence of laminin-1 and BMP 6,

labeled with BrdU and stained with (A) and without (B) mouse monoclonal anti-BrdU antibody.

Figure 12 is a photographic representation showing characterization of colony cells. **(A-E)** H & E staining showing colonies lined by various types of epithelia (Figure 12A). Under a higher magnification (oil lens) several types of epithelia are shown: **(B)** columnar, **(C)** cuboidal, **(D)** squamous or **(E)** a mixture. **(F, G)** Periodic acid Schiff (PAS) reaction staining of polysaccharides (pink, arrow) in the basement membrane surrounding the colong cells. **(H, I)** E-cadherin (E-cad), a marker of epithelial cells, detected by rat anti-mouse E-cadherin antibody and visualized by peroxidase-conjugated rabbit anti-rat immunoglobulins (brown).

Figure 13 is a photographic representation showing immunocytochemistry for insulin, glucagon and amylase. Insulin (Ins)-positive cells were stained with guinea pig anti-insulin serum and visualized by peroxidase-conjugated rabbit anti-guinea pit immunoglobulins. 15 : Ins-positive cells constituted and in some cases appeared to bud off from colonies (**A-E**). Glucagon (Glu)-positive cells (**F**) and amylase (Amy)-positive cells (**G, H**, arrows) stained with rabbit anti-glucagon and anti- α -amylase antibodies, respectively.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In accordance with the present invention, the inventors have identified that certain BMP molecules are expressed in the developing pancreas and are capable of stimulating
5 formation of insulin-positive cells. In a related embodiment, the inventors have identified that laminin-1 or laminin-1-containing extracellular matrix (ECM) also promotes formation of insulin-secreting cells.

Accordingly, one aspect of the present invention contemplates a method of stimulating or
10 otherwise facilitating formation of colonies of pancreatic cells containing insulin-secreting cells, said method comprising culturing pancreatic cells in the presence of a bone morphogenetic protein (BMP) or a functional derivative, homologue, mimetic, analogue or agonist thereof for a time and under conditions sufficient for colonies to form comprising insulin-secreting cells.

15 In a related embodiment, the present invention provides a method for stimulating or otherwise facilitating formation of mammalian colonies of pancreatic cells containing insulin-secreting cells, said method comprising culturing pancreatic cells in the presence of laminin-1 or laminin-1-containing ECM or a functional derivative, homologue, mimetic,
20 analogue or agonist thereof for a time and under conditions sufficient for colonies to form comprising insulin-secreting cells.

The term "pancreatic cells" is used herein in its broadest context to include any pancreatic or precursor cell which is acted upon by a BMP, generally but not exclusively in the
25 presence of laminin-1. Examples of such cells include progenitor cells, stem cells, duct cells or any other cell precursor. Reference to "progenitor cells" and "stem cells" includes any embryonic stem (ES) cell committed to a pancreatic cell lineage. All such cell types are encompassed by the term "pancreatic cells" or "pancreatic cell". Preferred pancreatic cells are of human, primate, livestock or laboratory test animal origin. Most preferred cells
30 are of human origin. Reference herein to a "subject" includes reference to a mammal and in particular a human.

In accordance with the present invention, the cell culture conditions necessary to promote the formation of colonies comprising insulin-producing cells from pancreatic cells include the presence of an ECM at concentrations suitable to promote the formation of colonies of pancreatic cells expressing insulin. It is preferable that the extracellular protein of the present invention is laminin-1. Generally but not exclusively the extra laminin-1 may be added to a cell culture medium from about 1 µg/ml to about 1000 µg/ml or more preferably from about 10 ug/ml to about 500 µg/ml or even more preferably from about 50 ug/ml to about 500 µg/ml to stimulate the formation of cystic colonies containing insulin positive cells. Although it preferable that ECM of the present invention is laminin-1 the present invention further contemplates the use of laminin-1, and its functional derivatives, homologues, mimetics or analogues including recombinant peptides, polypeptides and proteins that comprises a laminin-1 derived amino acid sequence.

Another aspect of the present invention contemplates a method for stimulating or otherwise facilitating formation of colonies of pancreatic cells containing insulin-secreting cells, said method comprising culturing pancreatic cells in the presence of laminin-1 or a laminin-1-containing ECM or a functional derivative, homologue, mimetic, analogue or agonist thereof, and a BMP or a functional derivative or homologue, mimetic, analogue or agonist thereof for a time and under conditions sufficient for colonies to form comprising insulin-secreting cells.

In still another aspect, the present invention provides a method of stimulating or otherwise facilitating formation of cystic epithelial colonies containing insulin-secreting cells, said method comprising culturing pancreatic cells in the presence of laminin-1 or a laminin-1-containing ECM or a functional derivative, homologue, mimetic, analogue or agonist thereof, and a BMP or a functional derivative or homologue, mimetic, analogue or agonist thereof for a time and under conditions sufficient for colonies to form comprising insulin-secreting cells.

Reference herein to a "bone morphogenetic protein" or "BMP" or a specific BMP such as but not limited to "BMP 2", "BMP 3", "BMP 4", "BMP 5", "BMP 6" and "BMP 7" includes reference to a polypeptide having BMP properties including the ability to stimulate or otherwise facilitate the formation of insulin-secreting cells. BMPs contemplated herein are those belonging to the TGF- β family of molecules. These terms also encompass functional derivatives, homologues, mimetics and analogues of the BMP molecule including homodimeric and heterodimeric forms. A derivative of a BMP is a mutant, part, portion or fragment including a BMP carrying a single or multiple amino acid substitution, addition and/or deletion to its amino acid sequence. Such derivatives, homologues, mimetics and analogues are considered functional in that they are capable of stimulating or otherwise facilitating formation of insulin-secreting cells. A derivative may also include an agonist or antagonist. An antagonist is particularly useful in the treatment or prevention of islet/cell hyperplasia/adenoma which causes the clinical syndrome of hyperinsulinemic hypoglycemia. Antagonists of some BMPs such as BMP 7 are particularly useful for the treatment of nesidioblastosis and other β cell hyperplasias such as hyperinsulinemia or hyperglycemic syndrome of infancy, β cell tumors (insulinomas) and/or pancreatic cancer (carcinoma) in mammals and in particular humans.

The present invention encompasses agonists and antagonists, even if they are not derivatives of a BMP. Antagonists may, for example, be chemical molecules identified from a chemical library or identified from natural product screening or may be secreted antagonists such as those which inhibit the signalling pathway of a BMP. Useful antagonists include Activin A and/or TGF- β or their homologues or derivatives.

In one aspect of the present invention, it is preferable that a BMP or combination of BMPs and/or laminin-1 or laminin-1-containing ECM alone or laminin-1 or laminin-1-containing ECM and a BMP are present in a culture of pancreatic cells to facilitate the formation of cystic epithelial colonies containing insulin-producing β cells. It is further contemplated that the concentration of the BMPs present in a culture of pancreatic cells may be modulated such that the cell culture is exposed to a regimen of BMPs and laminin-1 or laminin-1-containing ECM to stimulate the production of insulin-producing cells. In this

regard, any BMP may be used which have BMP properties for stimulating the formation of insulin-producing cells. The BMPs may be used either individually or together with each other or with any other member of the BMP family for the purpose stimulating the formation of insulin-producing cells. Specific BMPs contemplated herein include BMP 2, BMP 3, BMP 4, BMP 5, BMP 6 and BMP 7 or heterodimers thereof or any BMP member of the TGF- β family.

In yet a further related embodiment, the present invention contemplates a method of stimulating or otherwise facilitating the formation of colonies of pancreatic cells containing insulin-secreting cells, said method comprising culturing pancreatic cells in the presence of laminin-1 or laminin-1-containing ECM or a functional derivative, homologue, mimetic, analogue or agonist thereof and a BMP selected from the group consisting of BMP 2, BMP 3, BMP 4, BMP 5, BMP 6 and BMP 7 or functional derivatives or homologues or mimetics or analogues or agonists thereof under time and conditions sufficient for colonies to form comprising insulin-secreting cells.

The nucleotide and amino acid sequences for a range of BMP monomers are listed in the sequence listing. A summary of the sequence listing is shown just prior to the Examples. The present invention is not to be limited to the BMPs exemplified.

Other derivatives contemplated by the present invention include a range of glycosylation variants from a completely unglycosylated molecule to a modified glycosylated molecule. Altered glycosylation patterns may result from expression of recombinant molecules in different host cells.

A homologue of a BMP includes a structurally or functionally related BMP from another species or from within the same species and includes a polymorphic variant.

Analogues of the BMP molecules contemplated herein include, but are not limited to, modifications to side chains, incorporation of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and

other methods which impose conformational constraints on the proteinaceous molecule or its analogues.

Examples of side chain modifications contemplated by the present invention include
5 modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and
10 pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH_4 .

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal. The carboxyl group may be modified by carbodiimide activation *via* O-
15 acylisourea formation followed by subsequent derivitization, for example, to a corresponding amide.

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a
20 mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

25

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

30

097844-1-034501

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

- 5 Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids.

10

Crosslinkers can be used, for example, to stabilize 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having $(CH_2)_n$ spacer groups with $n=1$ to $n=6$, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide

- 15 and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of C_α and N_α -methylamino acids, introduction of double bonds between C_α and C_β atoms of amino acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C
- 20 termini, between two side chains or between a side chain and the N or C terminus.

These types of modifications may be important to stabilize BMPs for use in *in vitro* culture or as a therapeutic agent.

- 25 Preferably, the BMP is in recombinant form. The recombinant form of the BMP may comprise the identical amino acid sequence of the naturally occurring BMP or it may contain one or more amino acid substitutions, additions and/or deletions including a deletion of the start methionine. A nucleotide sequence encoding a BMP may also be optimized for expression in a particular host cell. This may result in a change in the amino
- 30 acid sequence such as the inclusion of a cleavage site.

Generally, the origin of BMP is the same as the origin of the pancreatic cells. For example, human-derived recombinant BMP is preferably used on human pancreatic cells. However, the present invention extends to "humanized" forms of non-human derived BMP molecules. A humanized murine BMP, for example, comprises a murine BMP backbone
5 with amino acid substitutions, additions and/or deletions to render the molecule functionally, structurally and/or antigenically similar to a human BMP.

The recombinant BMP molecules may also comprise homo- or heterodimeric forms. A heterodimer may comprise monomers from different BMPs from the same species or
10 different monomers from different specimens. BMPs of heterodimers include dimers between BMP 4 and BMP 5, BMP 4 and BMP 6, BMP 4 and BMP 7, BMP 2 and BMP 5, BMP 2 and BMP 6, BMP 2 and BMP 7, BMP 6 and BMP 7 and BMP 5 and BMP 6 amongst others. A BMP for use in a human subject is preferably of human origin or is a humaized form of a non-human form of BMP.

15 A "functional" BMP derivative, homologue, mimetic or analogue retains the ability to stimulate or otherwise facilitate the development of insulin-secreting cells *in vitro*. The "ability", however, may be more or less than a "parent" BMP.

20 Accordingly, another aspect of the present invention provides a method of stimulating or otherwise facilitating formation of colonies containing insulin-secreting cells from pancreatic cells, said method comprising culturing pancreatic cells in the presence of a BMP or a heterodimer formed from two or more BMPs or functional derivatives, homologues, mimetics, analogues or agonists forms thereof for a time and under
25 conditions sufficient for colonies to form comprising insulin-secreting cells.

In a preferred embodiment, the cells are cultured in the presence of both a BMP and a differentiation inducer such as but not limited to laminin-1 or a laminin-1-containing ECM or its functional derivatives, homologues, mimetics, analogues or agonists. A functional
30 laminin-1 derivative, homologue, mimetic or analogue is a molecule which is capable of inducing the production of insulin-secreting cells in the presence of a BMP.

More particularly, the present invention is directed to a method of stimulating or otherwise facilitating formation of colonies containing insulin-secreting cells from pancreatic cells, said method comprising culturing pancreatic cells in the presence of a BMP such as BMP 2, BMP 3, BMP 4, BMP 5 and/or BMP 6 or a heterodimer formed from two or more BMPs and laminin-1 or a laminin-1-containing ECM or functional derivatives, homologues, mimetics, analogues or agonists thereof for a time and under conditions sufficient for colonies to form comprising insulin-secreting cells.

10 A further aspect of the present invention contemplates the modulation of the expression of endogenous BMPs in order to facilitate the formation of colonies of insulin-secreting cells. In this aspect of the present invention, agonists are used to modulate the expression of genetic sequences encoding BMPs. Such agonist of bone morphogenetic gene expression may be small molecule agonists such as peptides polypeptides or proteins. The agonist of
15 BMP expression may be added to a culture medium in which cells are contained or be transferred directly to pancreatic cells by means such as but not limited to transfection.

Accordingly, this aspect of the present invention provides a method for the *in vivo* modulation of BMP expression, said method comprising culturing pancreatic cells in the
20 presence of an agonist of a BMP, wherein the agonist stimulates the expression of a BMP gene selected from the group of BMP 2, BMP 3, BMP 4, BMP 5, BMP 6, BMP 7 wherein the agonist can promote the formation of a heteromeric form of two or more BMPs.

The BMP and laminin-1 may co-exist in the culture medium or may be sequentially added
25 in either order. Sequential addition includes a time differential of from seconds or minutes to hours or days.

It is proposed in accordance with the present invention that cells generated *in vitro* are then transplanted to subjects with type 1 diabetes or a related condition. Generally, the
30 transplantation process requires appropriate treatment to prevent recurrent autoimmunity and/or immune-mediated rejection. A related condition to type 1 diabetes includes any

TOGETHER WITH

condition resulting in a lack of insulin following destruction of pancreatic islet cells. Reference to "type 1 diabetes" means insulin dependent type 1 diabetes or a related condition.

- 5 Generally BMP gene expression is required for pancreatic epithelial cell development, and in particular for the development of insulin-secreting cells. In this aspect of the invention, some members of the transforming growth factor (TGF)- β 1 superfamily antagonize the formation of colonies of insulin-secreting cells. In particular, TGF- β 1 and Activin A antagonize the formation of colonies of insulin forming cells. Thus, in this aspect of the
- 10 present invention the antagonistic activity of TGF- β 1 and Activin A in relation to the development of insulin-secreting cells may be alleviated by the addition of antagonist of TGF- β 1 and Activin A permitting the formation of colonies of insulin-secreting cells.

- Accordingly, this embodiment of the present invention provides a method of stimulating or
- 15 otherwise facilitating formation of colonies containing insulin-secreting cells from pancreatic cells, said method comprising culturing pancreatic cells in the presence of a BMP and in the presence of an antagonist of Activin A or TGF- β 1.

- The term "antagonize" means and includes reducing inhibiting, or otherwise adversely
- 20 affecting the normal function or activity of a molecule or molecules or agent or agents. In this regard, the functional result of such antagonism of Activin A or TGF- β 1 is the inability or at least a reduced capacity of Activin A or TGF- β 1 to inhibit the development insulin-producing cells from pancreatic cells, particularly in the presence of BMPs.

- 25 In accordance with this aspect of the present invention, there is provided a method of stimulating or otherwise facilitating the formation of colonies containing insulin-secreting cells from pancreatic cells, said method comprising culturing pancreatic cells in the presence of a BMP or a heterodimer formed from two or more BMPs or a functional derivative, homologue, mimetic, analogue or agonist forms thereof and an antagonist of
- 30 Activin A or TGF- β 1 for a time and under conditions sufficient for colonies to form comprising insulin-secreting cells.

Another aspect of the present invention contemplates a method for the treatment of a subject with type 1 diabetes or a related condition, said method comprising transplanting to said subject insulin-secreting cells produced following the *in vitro* culture of pancreatic
5 cells in the presence of a BMP or a heterodimer formed from two or more BMPs or functional derivatives, homologues, mimetics, analogues or agonists thereof and optionally in the presence of laminin-1 or laminin-1-containing ECM or derivatives, homologues, mimetics, analogues or agonists thereof for at time and under conditions sufficient for colonies to form comprising insulin-secreting cells.

10

An antagonist of Activin A or TGF- β 1 may be a peptide, polypeptide, protein, antibody, small or large chemical entities or combinations thereof and may be in isolated naturally occurring form or may be in a recombinant or chemically synthetic form. Screening for antagonists may be accomplished in any number of ways. In one method for the
15 identification of an antagonist of Activin A or TGF- β 1, pancreatic cells are incubated in the presence of a BMP and an inhibitory concentration of Activin A or TGF- β 1 and subjected to exposure by a potential antagonist. An immunoassay may be used to assay treated cells for the presence of insulin-producing cells.

20 There are many variations to assays for the screening agonists and antagonists and all are encompassed by the present invention.

In a related embodiment, the present invention provides a method for the modulation (e.g. reduction) of Activin A and TGF- β 1 mRNA levels in the pancreatic tissue of individuals
25 suffering from type 1 diabetes, said method comprising the administration of a therapeutic quantity of a sense or an antisense oligonucleotide or modified sense or antisense oligonucleotide complementary to an Activin A and TGF- β 1 mRNA over time and under conditions such that Activin A and TGF- β 1 mRNA levels are modified (e.g. reduced).

30 In a further related aspect, the present invention contemplates a method for reduction of expression of Activin A and TGF- β 1 mRNA, said method comprising the administration of

2009-04-01 10:54:20

a therapeutic quantity of an antisense oligonucleotide or modified antisense oligonucleotide complementary to regulatory regions of the Activin A and TGF- β 1 mRNA such as but not limited to 5' untranslated regions, 3' untranslated regions, introns or other polynucleotide sequences required for the expression of mRNA.

5

In yet a further related embodiment, the present invention provides a method for stimulating or otherwise facilitating the formation of colonies containing insulin-secreting cells from pancreatic cells in pancreatic tissues of an individual with type 1 diabetes, said method comprising the administration of a therapeutic quantity of an antisense
10 oligonucleotide complementary to an Activin A or TGF- β 1 mRNA capable of hybridizing to an Activin A or TGF- β 1 mRNA and using means provided by the biological system to reduce the level of Activin A or TGF- β 1 mRNA levels.

Another aspect of the present invention provides a method for modulating the quantity of
15 mRNA transcribed by an endogenous form of the human Activin A or TGF- β 1 mRNA gene, said method comprising the construction of polynucleotide sequences for the expression of an antisense polynucleotide sequence complementary to the regulatory regions of Activin A or TGF- β 1 mRNA gene, wherein expression of the antisense polynucleotide sequence permits the expression of the antisense oligonucleotide in
20 pancreatic cells facilitating the formation of colonies containing insulin-secreting cells.

As used herein, the term "antisense oligonucleotide" describes a sequence of nucleotides to form a polynucleotide that is complementary to a given target polynucleotide sequence. The antisense oligonucleotide may be complementary to an entire given sequence of a
25 polynucleotide or may be complementary to a region of the polynucleotide sequence. An antisense polynucleotide may be any length and hybridizes to a sequence under particular stringency conditions and may be produced so that it will hybridize to a complementary polynucleotide sequence only under certain hybridization conditions. Antisense molecules may be constructed such that they hybridize selectively under physiological conditions.
30 Selective hybridization under physiological conditions requires that the antisense oligonucleotide should comprise at least 10 contiguous nucleotides which are

complementary to the target polynucleotide sequence and in some instances it may be required that the complementarity of an antisense molecule may be interrupted by a sequence of one or more nucleotides in length, such nucleotide sequences may hybridize to their target sequences under specified conditions.

5

The term “modified oligonucleotide” as used herein describes an oligonucleotide that has at least two nucleotide elements covalently linked by a phosphodiester linkage between the 5’ end of one nucleotide and the 3’ end of the other nucleotide and a chemical group not normally associated with nucleic acids covalently linked to the polynucleotide. Preferred synthetic internucleotide linkages include but are not limited to phosphorothioates, alkyl phosphonates, phosphorodithioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonates, carbamates, phosphate triesters, acetamides and carboxymethyl esters. The term “modified oligonucleotide” also encompasses oligonucleotides with a covalently modified base and or sugar. Modified nucleosides include but are not limited to covalently attached molecules other than a hydroxyl group at the 3’ position and other than a phosphate group at the 5’ position. Thus, modified oligonucleotides may include a 2’-O-alkylated ribose group. In addition, a modified oligonucleotide may comprise sugars such as but not limited to arabinose or ribose. A modified oligonucleotide includes a C5 propyne modification.

20

Generally, the pancreatic cells cultured *in vitro* are not from the subject being treated. The term “pancreatic cells” is as described above. Any source of pancreatic cells may be used. One particularly useful source is fetal pancreas cells.

25 A further aspect of the present invention provides for the use of a BMP or a heterodimer formed from two or more BMPs in the manufacture of an agent for use in stimulating or otherwise facilitating formation of colonies of insulin-secreting cells from pancreatic cells following *in vitro* culture of said pancreatic cells.

In an alternative embodiment, the BMP is administered to a subject with type 1 diabetes or a related condition in order to stimulate the proliferation and differentiation of cells and to thereby restore insulin secretion in the host pancreas.

5 Accordingly, the present invention contemplates a method for the treatment of a subject with type 1 diabetes or a related condition, said method comprising administering to said subject an effective amount of a BMP or a heterodimer formed from two or more BMPs or derivatives, homologues, mimetics, analogues and/or agonists thereof for a time and under conditions sufficient to facilitate insulin secretion in the pancreas of said subject.

10

Generally, the time of conditions for administration of the BMP are such to permit stimulation of the proliferation and differentiation of pancreatic cells into insulin-secreting β cells. Generally, reference to "facilitating" insulin secretion includes initiating, enhancing, promoting or inducing insulin secretion.

15

The BMP may be administered alone or in combination with other agents such as laminin-1 and/or immune suppressive agents. In addition to laminin-1, other agents include cytokines, interferons and interleukins as well as laminin-1-containing ECM.

20 Accordingly, the present invention further provides a composition comprising a BMP or a heterodimer formed from two or more BMPs and optionally one or more other therapeutic agents and one or more pharmaceutically acceptable carriers and/or diluents.

The composition is for use in stimulating proliferation and differentiation of pancreatic
25 cells into insulin-secreting β cells. The term "for use" in this context also means "when used" for this purpose.

The composition according to this aspect of the present invention may be referred to as a "pharmaceutical composition".

30

109760-11016260

The preparation of pharmaceutical compositions is well known in the art and reference can conveniently be made to Remington's Pharmaceutical Sciences, Mack Publishing, Company, Easton, PA, USA.

- 5 Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients including therapeutic agents can also be incorporated into the compositions. In one embodiment, laminin-1 is also included in the composition.

- Alternatively or in addition, anti- α_6 integrin antibody, GoH3, is included. Alternatively, or in addition to, the component is an agent capable of inhibiting P13K, MAP kinase or actin polymerization. This is predicated on the observation that blocking laminin-1 binding to α_6 integrin receptors by the monoclonal antibody GoH3 or inhibiting P13K, MAP kinase or actin polymerization downstream of α_6 integrins abolished cell division and significantly increased β cell number in fetal mouse pancreas cell cultures. These findings suggest that the α_6 integrins normally mediate a proliferative signal from laminin-1 through the MAP kinase pathway and exert an inhibitory effect on β cell survival and cell differentiation.

- Administration may be by any number of means including intravenous, intraperitoneal, subcutaneous, intranasal, intrapharyngeal, intrabronchial, oral or rectal administration. The composition may be in a liquid, solid or gas or vapour form. Administration may be by pump, injection, tablet or *via* aerosol means. Delivery may also be "on-site" such as during surgery, biopsy or other interventionist therapy. Targeted delivery may also be accomplished.

- 30 The effective amount of BMP includes an amount in the range of from about 10 $\mu\text{g/kg}$ body weight to about 1 mg/kg body weight or from about 100 $\mu\text{g/kg}$ body weight to about

TOP SECRET

500 µg/kg body weight. Expressed alternatively, the effective amounts are preferably in the order of 0.5-100 mg/per dose/subject.

In a further embodiment, the present invention provides a two part pharmaceutical pack comprising a first compartment comprising a BMP or a functional derivative, homologue, mimetic or analogue thereof at a second compartment comprising laminin-1 or laminin-1-containing ECM or a functional derivative, homologue, mimetic or analogue thereof.

In one embodiment, the contents of both compartments are mixed together prior to use or are prepared separately and administered simultaneously or sequentially.

The above-mentioned pharmaceutical pack may further comprise instructions for use.

In an additional embodiment, the method may be practised by administering DNA encoding the BMP. The DNA may be cDNA or genomic DNA or is a DNA:RNA hybrid.

In still yet another embodiment, the present invention extends to the use of a BMP or a heterodimer formed from two or more BMPs in the manufacture of a medicament in the treatment of type 1 diabetes or a related condition in a subject.

The treatment protocol proposed herein may be extended to people genetically at risk from developing type 1 diabetes or a related condition or who are at risk for non-genetic reasons such as age. Accordingly, the present invention extends to the treatment and/or prophylaxis of type 1 diabetes or a related condition.

In yet another embodiment, an antagonist of a BMP is used in the manufacture of a medicament for the treatment or prophylaxis of islet/β cell hyperplasia/adenoma which causes the clinical syndrome of hyperinsulinemic hypoglycemia or other related condition.

Accordingly, another aspect of the present invention contemplates a method for the treatment or prophylaxis of islet/β cell hyperplasia adenoma or a related condition

- including pancreatic cancer, said method comprising administering to a subject an effective amount of an antagonist of a BMP for a time and under conditions sufficient to inhibit the formation or maintenance of insulin-producing β cells. Preferably, the antagonist is an antagonist of a BMP such as BMP 7 and the condition is nesidioblastosis.
- 5 An antagonist may be a derivative of a BMP or it may be, for example, identified following screening of a natural product or chemical library.

- Aspects of this invention are described in Jiang *et al.* (1999) which is incorporated herein by reference. This article describes the development of a low cell density serum-free
- 10 culture system for dissociated pancreatic cells from the 13.5-day mouse fetus and investigated the effects of extracellular matrix proteins on differentiation of islet β cells. After four days in culture, total cell number decreased by two-thirds, but insulin-positive cell number increased 10-fold. Both of collagens I and IV inhibited β cell survival (by >50%), whereas fibronectin had no effect. In the presence of soluble laminin-1, however,
- 15 the number of β cells increased linearly by 60-fold without an increase in the total cell number; glucagon-positive cell number was unchanged, and somatostatin and pancreatic polypeptide-positive β cells were not detected. The effect of laminin-1 was completely blocked by a monoclonal rat anti-laminin-1 antibody. In the presence of laminin-1, the thymidine analogue BrdU, was incorporated into only 2.5% of cells, which were mainly
- 20 insulin-negative at days 1-3. Laminin-1 appeared, therefore, to induce differentiation of cells from precursor cells in day 13.5 fetal pancreas. Laminin-1 was shown to be expressed in the epithelial basement membrane of the 13.5 to 17.5 day fetal pancreas. These findings show a role for laminin-1 in promoting differentiation of pancreatic β cells.

- 25 The present invention is further described by the following non-limiting Examples.

SECRET

- 29 -

DESCRIPTION	SEQUENCE IDENTIFIER
Activin A forward primer	<400>27
Activin A reverse primer	<400>28
β actin forward primer	<400>29
β actin reverse primer	<400>30

BMP = bone morphogenetic protein
BMP 4/4 = BMP 4 homodimer
BMP 7/7 = BMP 7 homodimer
BMP 4/6 = BMP 4 and BMP 6 heterodimer
BMP 4/7 = BMP 4 and BMP 7 heterodimer

FOSTER-F018260

- 30 -

EXAMPLE 1

Cloning and expression of mouse BMP

1 The coding sequences of BMPs 3, 4, 6 and 7 were amplified from a 7 dpc mouse cDNA
5 library by a PCR-based approach. This yielded two fragments for BMP 4 and BMP 7,
representing the pro-domain and active peptide (cystine knot). For BMP 6 and BMP 3,
only the active peptide region was amplified. The PCR products were cloned into pGEM
T-easy and the nucleotide sequences determined. Individual clones containing inserts
10 which possessed only the consensus sequence for each fragment were then selected. The
inserts representing the pro-domains of BMP 4 and 7 were excised from these clones with
MluI and the isolated fragments ligated into the *AscI* site of pEFBOS myc or pEFBOS
glu/glu. Recombinant plasmids resulting from this ligation contained the pro-domain N-
terminal to the epitope tag (myc or glu). These plasmids were subsequently digested with
15 *MluI* and ligated to *MluI* fragments representing the active peptides to yield a series of
vectors (Figure 1). Restriction mapping and sequence analysis was then used to verify the
correct configuration of the resultant recombinants.

EXAMPLE 2

BMP-producing CHO cell lines

20 Transient transfections in COS cells were evaluated by immunoblotting (Figure 2) to
confirm that the vectors encoded proteins of the correct size, with BMP activity (see
below). In order to secure a more reliable source of these factors, the inventors established
CHO cell lines stably transfected with the vectors in the presence of a plasmid encoding
25 puromycin resistance. Approximately 20 puromycin-resistant clones representing each
vector type were isolated and conditioned medium from each clone was bioassayed for
BMP activity to identify the highest producer cell line for each transfection. Media from
cells expressing BMPs 4/4, 7/7, 4/6 and 4/7 contained significant activity, compared to
medium conditioned to untransfected CHO cells (Figure 3). Expression of BMP 3 has not
30 yet been assayed. In the case of BMP 6, significant BMP activity was never detected so

- 31 -

cell lines were selected on the basis of the level of myc epitope tagged protein in conditioned media.

EXAMPLE 3

BMP bioassay

5

BMP activity was measured in the C2C12 cell bioassay, in which BMPs transform C2C12 myoblasts into alkaline phosphatase-containing osteoblasts (Katagiri *et al.*, 1994). Briefly, CHO cells were plated at a density of around 5×10^6 per 75 cm² flask in serum-free
10 HYBRIDOMA medium (Gibco BRL Life Technology) (SFHM) containing 10% v/v FCS. Once the cells had reached confluency, the medium was removed, the cells washed twice with SFHM and 10 ml of SFHM then added to each flask. The cells were cultured for four days and the conditioned medium collected, filtered through a 2 micron filter and stored at 4°C.

15

2 x 10³ C2C12 cells were plated into each well of a 96-well tissue culture plate in DME/10% v/v FCS. Twenty-four hours later, the medium was removed and replaced with 100 µl SFHM/1% v/v FCS. 50 µl of each conditioned medium was added in duplicate to the top row of the 96-well plate and the volume of these wells then made up to 200 µl.
20 Using a multi-channel pipette, 100 µl from each well was then serially transferred to subsequent rows thus diluting the conditioned medium 2-fold with each transfer. After incubation for five days, the media were discarded and the cells washed with normal saline. Cells were lysed for 10 mins at room temperature (RT) in 100 µl 0.5% v/v TritonX-100 and 100 mM diethanolamine (pH 9.5) in normal saline. To each well was then added
25 an aqueous solution containing 10 mM diethanolamine, 1 mg/ml *p*-nitrophenyl phosphate (PNPP) and 0.5 mM MgCl₂. The yellow reaction product catalyzed by alkaline phosphatase was allowed to develop for 10-60 mins before reading absorption at 415 nm.

- 32 -

EXAMPLE 4

Preparation and culture of fetal mouse pancreatic cells

5 Dissociated fetal pancreas cells were prepared from 13.5 dpc CBA mice. Pregnant mice at 13.5 dpc were killed by cervical dislocation and fetuses collected into ice cold sterile mouse tonicity phosphate-buffered saline (MTPBS). Fetal pancreata were harvested under an Olympus dissection microscope into RPMI 1640 medium and dissociated in a shaking water bath at 37°C for 11 mins in $\text{Ca}^{2+}/\text{Mg}^{2+}$ -free PBS containing 0.5% v/v trypsin/EDTA as described for testis by Bucci *et al.* (1986). After dissociation, trypsin was inactivated by
10 addition of 8% w/v bovine serum albumin (BSA, fraction V) (Sigma, St. Louis, USA). The tissue was aspirated several times in a pipette, passed through a 27 gauge needle to make a single cell suspension and then rinsed in 10 $\mu\text{g}/\text{ml}$ DNase I (Promega, Madison, USA) in RPMI 1640 for 10 mins to reduce cellular aggregates. Cell suspensions were filtered through a 70-100 μm steel mesh, centrifuged at 400 x g for 5 mins and the supernatant
15 discarded. The cell pellet was resuspended in HYBRIDOMA medium and stored on ice. Cells were counted under a haemocytometer and viability was determined by exclusion of 0.2% v/v trypan blue dye. Pancreatic cells were plated in 8 chamber slides (Nunc) at 1.5×10^4 cells/well in 0.3 ml HYBRIDOMA medium. 500 UI/ml penicillin and 500 $\mu\text{g}/\text{ml}$ streptomycin. The cells were cultured in 10% v/v CO_2 , 90% v/v air at 37°C with 100%
20 humidity for four days in the presence of factors such as laminin-1 and BMPs.

EXAMPLE 5

Laminin-1

25 Laminin-1, prepared from murine Englebreth-Holm-Swarm (EHS) tumour cell basement membrane was purchased from Gibco BRL. To prevent polymerization, it was manipulated at 4°C, dialyzed at 4°C against HYBRIDOMA medium and diluted directly into chilled medium before addition to pancreas cells in culture.

EXAMPLE 6***Antibodies***

Guinea pig anti-porcine insulin antiserum was from Chemicon. Mouse monoclonal anti-
5 bromodeoxyuridine (BrdU) IgG2a (Clone BU-1) was from Amersham Life Science.
Rabbit antisera to porcine glucagon, human somatostatin and human pancreatic
polypeptide were from Dako.

10 Rat monoclonal antibody (clone NK1-GoH3, IgG2a) that specifically blocks laminin-1
binding to α_6 integrins (Sonnenberg *et al.*, 1990; Almeida *et al.*, 1995; Falk *et al.*, 1996)
was from Chemicon International (Temucula, USA). Goat polyclonal immunoglobulin to
 α_6 (clone P1B5) and integrin β_4 (clone 3E1) were from Gibco BRL. Mouse monoclonal
IgM antibody to α -DG, IIH6, was provided as hybridoma supernatant from Howard
15 Hughes Medical Institute, University of Iowa, College of Medicine (Iowa City, USA). The
total protein concentration of IIH6 hybridoma supernatant was measured by the Bradford
method (Bio-Rad, Hercules, USA). A non-blocking mouse monoclonal antibody to α -DG
(clone V1A4-1) was from Upstate Biotech (Lake Placid, USA). Rat monoclonal IgG2a
(control for NK1-GoH3), mouse IgM (control for IIH6) and rat monoclonal IgG2a to
20 integrin β_1 (clone 9EG7) from Pharmingen (San Diego, USA) were dialyzed against
HYBRIDOMA medium at 4°C prior to use. Guinea pig antiserum to porcine insulin was
from Dako (Glostrup, Denmark). Mouse monoclonal IgG2a to BrdU (clone BU-1) was
from Amersham Life Science (Buckinghamshire, England). Rabbit antiserum to porcine
glucagon and to human somatostatin and pancreatic polypeptide were from Dako.
Fractionated rabbit antiserum to human α -amylase, a marker of acinar cells, and to laminin,
25 were from Sigma Chemicals (St. Louis, USA).

Heparin, a known blocker of laminin-1 binding to α -DG (Ervasti and Campbell, 1993; Pall
et al., 1996) was from Sigma. Wormannin and Ly294002, inhibitors of PI3K (Powis *et al.*,
1994; Vlahos *et al.*, 1994), genistein and herbimycin, inhibitors of Src family tyrosine
30 kinases (Uehara *et al.*, 1986) associated with focal adhesion kinase (FAK) (reviewed by
Clarke and Brugge, 1995; Ilic *et al.*, 1997), and PD98059, an inhibitor of MEK1 (Dudley

et al., 1995) were from Calbiochem (La Jolla, USA). Cytochalasin D, an inhibitor of actin polymerization was from Sigma.

EXAMPLE 7

5

Immunocytochemistry

After four days in culture, cells were washed twice with warm MT-PBS and fixed with a 4% v/v paraformaldehyde for 10 mins. In some cases, 100 μ M BrdU was added to label proliferating cells 12 hours before fixation and detection with monoclonal antibody to
10 BrdU and FITC-labelled rabbit anti-mouse immunoglobulin. For immunoperoxidase staining, endogenous peroxidase was blocked by 3% v/v H₂O₂ in methanol for 8 mins and, prior to addition of primary antibody, non-specific protein binding was blocked by incubation for at least 30 mins in MTPBS containing 2% w/v BSA or 2% v/v normal rabbit serum. Controls were performed by replacing primary antibody with pre-immune serum
15 from the appropriate species. Tissue sections or cells were incubated with primary antibodies for 90 min RT, followed by three thorough washes with MTPBS. For immunoperoxidase staining, horseradish peroxidase-conjugated rabbit anti-guinea pig, swine anti-rabbit or rabbit anti-mouse immunoglobulins (Dako) diluted 1:80 were added for 30 mins at RT followed by thorough washes; colour was developed with 3,3'-
20 diaminobenzidine/H₂O₂ for 4-8 mins and slides counterstained with haematoxylin.

EXAMPLE 8

Pancreatic cell colonies

25 A pancreatic cell colony was defined as a spherical collection of 20 cells. Colonies were counted under a x10 power objective with an eyepiece graticule.

EXAMPLE 9***Cell immunoperoxidase staining and quantitation***

Fetuses at 15.5 and 18.5 dpc from homozygous (-/-) or heterozygous (+/-) α_6 integrin gene
5 targeted (Georges-Labouesse *et al.*, 1996) or wild type mice were fixed overnight in
Bouin's solution. After standard dehydration processing, fetuses were embedded into
paraffin and sectioned at 7 μ m. Cultured pancreatic cells were washed three times with
warm mouse tonicity phosphate buffered saline (MT-PBS) and fixed with 4%
paraformaldehyde (PFA) for 10 mins. Endogenous peroxidase was blocked by 3% v/v
10 H_2O_2 in methanol for 8 mins. Prior to antibody staining, non-specific protein binding was
blocked by incubation for at least 30 mins with MT-PBS containing 2% w/v bovine serum
albumin or 2% v/v normal rabbit serum. Controls were performed by replacing first
antibody with pre-immune serum from the appropriate species. Cell were incubated with
primary antibodies for 90 mins at room temperature, followed by three thorough washes
15 with MT-PBS. Horseradish peroxidase-conjugated rabbit anti-guinea pig or swine anti-
rabbit immunoglobulins (Dako) were added for 30 mins at room temperature followed by
thorough washes. Immunoperoxidase was detected with 3,3'-diaminobenzidine/ H_2O_2 for
4-8 mins, and slides were counterstained with haematoxylin.

20 Immunoperoxidase positive and negative cells were quantitated in the central strip of each
culture chamber (a 90 x 90 mm square) under a microscope equipped with an eyepiece
graticule (Olympus, Japan) at x40 power and calibrated with a micrometer (Olympus). All
data are presented as mean \pm s.e.m. of at least three independent experiments.

25

EXAMPLE 10***Immunofluorescence sliding***

In some cultures, 100 μ M BrdU (Sigma) was included to label proliferating cells; cells
were fixed by 4% PFA at days 1, 2, 3 and 4 for insulin and BrdU double
30 immunofluorescence staining. Fetuses were directly snap-frozen in liquid nitrogen, section
at 8 μ m, the sections air-dried for 40-60 mins and fixed in cold (-20°C) acetone for 10

- 36 -

mins. Pre-treatment and primary antibody incubations were as described above, followed by incubation with Texas Red-conjugated goat anti-guinea pig immunoglobulins (Vector Laboratories, Burlingame, USA) or fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse, -rat or -goat or swine anti-rabbit immunoglobulins (Dako) for 30 mins at room temperature and three thorough washes. Slides were observed and photomicrographed under a Zeis Axiopot fluorescence microscope.

EXAMPLE 11

Statistics

10

Differences between groups were analyzed by the non-parametric Mann-Whitney U test.

EXAMPLE 12

Effect of BMP

15

The bioactivity of BMPs (Figure 3) was both a function of their concentration and composition. For example, 4/7 heterodimers were more active than 4/4 homodimers (Aono *et al.*, 1995).

20

In the presence (but not absence) of laminin-1, BMP 6/6, BMP 7/7 and BMP 4/7 stimulated fetal pancreas cells to proliferate and form colonies, which were mainly insulin-negative after four days culture (Figure 4). BMP 4/4 and BMP 4/6 did not promote colony formation. The effect on colony formation was dose-dependent (Figure 5). After eight days in culture the colonies had grown much larger and contained central, insulin-positive cells (Figure 6). BrdU added for 12 hrs in culture labelled cells in the colonies (Figure 7), providing evidence that the colonies were formed by cell proliferation rather than cell aggregation. A range of candidate growth factors including IGF, TGF and, HGF, EGF, KGF, Activin A, betacellulin, PTrP, gastrin, PYY and TRH were individually unable to promote proliferation or colony formation of these cells.

30

In summary, BMP 7/7, 4/7 and 6/6 are growth factors for fetal pancreas cells that stimulate formation of colonies containing insulin-positive cells. The inventors propose that the BMPs can be used to generate insulin-secreting bells in the presence of laminin-1 and possibly other differentiation inducers. β cells generated *in vivo* with these BMPs could be transplanted to treat people with type 1 diabetes, in conduction with appropriate treatment to prevent recurrent autoimmunity and immune-mediated rejection. These BMPs could also be delivered *in vivo* to patients with type 1 diabetes to stimulate the proliferation and differentiation of cells and thereby restore insulin secretion in the host pancreas.

EXAMPLE 13

α_6 integrin blockade stimulates cell development

To investigate the role of α_6 integrin in laminin-1 induced β cell differentiation, pancreatic cells were cultured with laminin-1 and rat monoclonal IgG2a antibody GoH3, which specifically blocks laminin-1 binding to α_6 integrins. GoH3 caused cells to appear more uniformly spherical rather than flattened with laminin-1 alone and resulted in a dose-dependent increase in the number of both total cells and β cells. The increase in total cell number was due to the increase in β cell number. For example, at 40 $\mu\text{g/ml}$ GoH3, β cell number per well increased from 2265 ± 240 (mean \pm s.e.m. $n=3$) to 6886 ± 364 and total cell number from 4016 ± 650 to 7188 ± 228 . Rat IgG2a control antibody had no effect on cell number. β cell number in the presence of GoH3 alone was similar to that in medium only. Thus, the effect of GoH3 to increase β cell differentiation depended on the presence of laminin-1 and GoH3 did not mimic the effect of laminin-1. The proportion of glucagon-positive cells was no higher in the presence of GoH3 and somatostatin- and PP-positive cells and acinar cells were not detected.

To determine if GoH3 affected cell proliferation, 100 μM BrdU was added with laminin-1 (200 $\mu\text{g/ml}$), with and without GoH3 and BrdU-positive cells analyzed at days 1-4. In the absence of GoH3, 2.5% of cells were BrdU-positive; in the presence of GoH3, BrdU-positive cells could not be detected.

EXAMPLE 14***Inhibition of PI3K, actin polymerization or MEK1 stimulates cell development***

5 Specific inhibitors were used to block α_6 integrin downstream signalling. To determine if PI3K has a role in laminin-1 mediated β cell differentiation, 13.5 dpc fetal mouse pancreas cells were cultured for four days with the PI3K inhibitors, Wortmannin or Ly294002, at concentrations (0.1-100 μ M) reported to be non-toxic for pancreas cells (Gao *et al.*, 1996). Both Wortmannin and Ly294002 significantly increased total and β cell numbers in a dose-
 10 dependent manner. Without laminin-1, the number of β cell was not affected by either agent, indicating that differentiation in the presence of laminin-1 requires inhibition of PI3K. Blocking formation of F-actin by ecytochalasin D may inhibit the Ras-PI3K-MEK1 signalling cascade. Cytochalasin D increased laminin-1 induced β cell differentiation, similar to Wortmannin or Ly294002 consistent with a role for the actin cytoskeleton in cell
 15 differentiation. MEK1 is downstream from PI3K. Inhibition of MEK1 by PD98059 also increased laminin-1 mediated β cell differentiation. Src family tyrosine kinases are associated with focal adhesion kinase (FAK), which may signal MAP kinase *via* Ras. However, inhibiting Src kinases by genistein or herbimycin A did not affect laminin-1 mediated β cell differentiation.

20

EXAMPLE 15 ***α_6 integrin blockade stimulates expression of α_6 integrin and α -DG***

To examine α_6 integrin and α -DG expression under different conditions, cultured cells
 25 were studied by indirect immunofluorescence. In the absence of laminin-1, cells positive for α_6 integrin or α -DG were not observed after two or four days in culture. In the absence of laminin-1, approximately 10% of cells were positive for both α_6 integrin and α -DG at day 2 and four. However, at day 2 in the presence of laminin-1 and GoH3, the proportion of cells positive for both α_6 integrin and α -DG markedly increased to 60-70%.

30

EXAMPLE 16***Islet cell development in α_6 integrin-deficient mice***

5 The morphology of the pancreas at 15.5 and 18.5 dpc appeared normal in α_6 integrin-deficient mouse fetuses. Immunostaining for glucagon, insulin, somatostatin and pancreatic polypeptide revealed that the distribution and number of islet cells were similar in homozygous (-/-) and heterozygous (+/-) mutants and wild type (+/+) fetuses at 18.5 dpc. At 15.5 dpc, the numbers of α - and β -cells were similar among -/-, +/- and +/+ fetuses, and PP cells were not observed.

10

EXAMPLE 17 ***α -dystroglycan blockade inhibits cell development***

15 To investigate the role of α -DG in laminin-1 induced β cell differentiation, 13.5 dpc fetal mouse pancreas cells were cultured with laminin-1 and either the mouse IgM monoclonal antibody (IIH6) which blocks laminin-1 binding to α -DG (Ervasti and Campbell, 1993; Durbeej *et al.*, 1995; Brown *et al.*, 1999) or heparin which also blocks laminin-1 binding to α -DG (Ervasti and Campbell, 1993), IIH6 significantly decreased ($p < 0.01$) the number of both total and β cells whereas mouse IgM control antibody (1-20 μ g/ml) had no effect.

20 Heparin at 100 μ M also significantly decreased ($p < 0.05$) the number of total and β cells. Moreover, at this concentration, heparin blocked the effect of α_6 integrin antibody GoH3 to increase β cell differentiation. These findings indicate that laminin-1 signalling *via* α -DG promotes islet-cell survival and β cell differentiation but that this effect is inhibited by laminin-1 signalling *via* α_6 .

25

EXAMPLE 18***In vitro culture of pancreatic progenitor cells***

30 Pancreata were dissected from embryonic day (E)15.5 CBA mouse fetuses and dissociated into single cells as described (Jiang *et al.*, 1999). Briefly, dissected pancreas was digested with trypsin/EDTA for 15 minutes at 37°C in a shaking water bath. Cells were counted in a

haemocytometer and viability determined by trypan blue dye exclusion. Each fetal pancreas yielded 50,000 viable cells ($48,509 \pm 11,299$, $n = 14$). Dissociated cells were plated in 8 well chamber slides (Nunc, Naperville, USA) at 7.5×10^4 cells/well in 0.3 ml AIM V medium supplemented with N-2 (1: 100, Gibco BRL Life Technologies, Gaithersburg, USA), 500 UI/ml penicillin and 500 μ g/ml streptomycin. Laminin-1 (160 μ g/ml), purified from murine Engelbreth-Holm-Swarm tumor basement membrane (Becton Dickinson Labware, Bedford, USA), was overlaid on cells in the presence of various growth factors. Cultures were incubated in 10% CO₂ 90% air at 37°C, for up to 6 days. Recombinant human BMP 6 and BMP 5, recombinant human TGF- β 1 and recombinant activin A were purchased from R&D Systems (Minneapolis, USA). These factors, dissolved at a concentration of 10 ng/ μ l in mouse tonicity phosphate buffered saline (PBS) containing 0.1% w/v bovine serum albumin (BSA), were added at the start of culture. Phase contrast images of colonies were photographed with Olympus IX70 digitized camera.

EXAMPLE 19

Colony quantitation

Colony formation was assessed at day 6 of culture. A colony was defined as a cellular sphere $\geq 30 \mu$ m in diameter, which contained more than 20 cells. The number of colonies per well was counted directly under a inverted microscope at x10. Colony counts were performed using a blind design.

EXAMPLE 20

Immunocytochemistry and histocytochemistry

After 6 days of culture, pancreas cell colonies were harvested by digestion with dispase (Becton Dickinson Labware). Following inactivation of dispase by addition of 8% w/v BSA, the colonies were fixed in 4% w/v paraformaldehyde (PFA), embedded into 1% low melting point agarose gel and processed for histological sections (5 μ m) using standard procedures.

For immunoperoxidase staining, endogenous peroxidase was blocked by 3% H₂O₂ in methanol for 8 minutes. Before addition of antibody, non-specific protein binding was blocked by incubation of tissues for at least 30 minutes with PBS containing 2% w/v BSA or 2% normal rabbit serum. Negative controls were performed by replacing first antibody with pre-immune serum from the appropriate species. Colony sections were incubated with primary antibodies for 90 minutes at 25°C, followed by three washes with PBS. Horseradish peroxidase conjugated rabbit anti-guinea pig, swine anti-rabbit and rabbit anti-mouse immunoglobulins (Dako, Glostrup, Denmark; 1:80) were added for 30 minutes at 25°C, followed by thorough washes. Immunoperoxidase was detected with 3, 3'-diaminobenzidine/H₂O₂ for 4-8 minutes and slides counterstained with haematoxylin.

For immunofluorescence staining, fluorescein isothiocyanate-conjugated rabbit anti-mouse immunoglobulins (Dako) were added for 30 minutes at 25°C, followed by three thorough washes.

Guinea pig anti-porcine insulin antiserum (final 1:200), rat monoclonal anti-E-cadherin IgG2a (clone ECCD-2) (1:100) and rabbit antiserum to porcine glucagon (1:100) and to human somatostatin (1:200) were purchased from Dako (Glostrup, Denmark). Fractionated rabbit antiserum to human α -amylase, a marker of acinar cells, was from Sigma. Bromodeoxyuridine (BrdU) at 100 μ M was added to medium for the last 16 hr of cell culture and mouse monoclonal anti-BrdU IgG1 (Clone BU-33) was purchased from Amersham Pharmacia Biotech (Buckinghamshire, UK).

The periodic acid Schiff (PAS) reaction (Bancroft and Stevens, 1982) was used to stain basement membranes.

EXAMPLE 21***RT-PCR analysis of mRNA transcripts***

Fetal pancreata were removed under a dissection microscope and snap-frozen on dry-ice.

5 Total RNA was extracted with phenol/guanidine isothiocyanate-based RNAzol B (Cinna/Biotex, Houston, USA). RNA was treated by DNase I and then reverse transcribed with Superscript II reverse transcriptase (GibcoBRL) in 1x transcription buffer containing 0.5 μ M oligo(dT)16-18 primer (GibcoBRL) and 400 μ M dNTPs. Aliquots of the cDNAs were amplified by PCR in 1x PCR buffer (Perkin, Elmer, USA) containing 200 μ M dNTPs,

10 1 μ M of each primer pair, 1.5 mM Mg^{++} and 1 U Taq polymerase. The following primers were employed: BMP-2 (5' GTGGAGGAACCTCCAGAGATGAGTG 3' [<400>15]; 5' ATTTATTCTTGCTGTGCTAACGACAC 3' [<400>16], 852 bp), BMP-4 (5' CATCCCAGGGACCAGTGAGAGCTCTG 3' [<400>17]; 5' TCCGCCCTCCGGACTGCCTGATCTC 3' [<400>18], 863 bp), BMP-5 (5' 15 GAGCACAGCAAGGCTTGGGAACATG 3' [<400>19]; 5' GCTGGAGATTATAATACCAGTGAAC 3' [<400>20], 240 bp), BMP-6 (5' GTTCTTCAGACTACAACGGCAGTGAG 3' [<400>21]; 5' GTTAGGAATCCAAGGCAGAACCATG 3' [<400>22], 402 bp), BMP-7 (5' GTGTGGCAGAAAACAGCAGCAGTGAC 3' [<400>23]; 5' 20 GACATCGAAGATTTGGAAAGGTGTG 3' [<400>24], 401 bp), TGF β -1 (5' ACCAACTATTGCTTCAGCTCCACAG 3' [<400>25]; 5' GCAGGAGCGCACAATCATGTTGGAC 3' [<400>26], 317 bp), activin A (5' CTTGGAGTGCGACGGCAAGGTCAAC 3' [<400>27]; 5' CATTTTCTCTGGGACCTGGCGACTC 3' [<400>28], 372 bp) and the "housekeeping"

25 gene β actin (5' GTGGGCCGCCCTAGGCACCA 3' [<400>29], 5' CTCTTTGATGTCACGCACGATTTC 3' [<400>30], 530 bp). PCR reactions were performed for 35 cycles (94°C, 30 seconds; 55°C, 30 seconds; 72°C, 30 seconds) and amplified products separated in 1.5% w/v agarose gels.

EXAMPLE 23***Statistics***

Multi-variable experiments were analyzed by ANOVA and differences between groups by Student *t* test. Data are presented as mean \pm s.d. of at least three experiments.

EXAMPLE 24***Effects of growth factors on pancreatic cells***

A low cell density culture system was used to demonstrate that fetal pancreas progenitor cells differentiate into insulin-positive β cells in the presence of laminin-1 (Jiang *et al.*, 1999). When this system was modified by replacing HYBRIDOMA medium with AIM V medium supplemented with N-2, increasing the cell density to 925 cells/mm² and decreasing laminin-1 concentration from 200 μ g/ml to 160 μ g/ml, a low frequency of cystic colonies was observed (Figure 8). These conditions established a baseline on which the effects of other factors were studied.

In order to ascertain which members of the TGF- β superfamily might be relevant to pancreas development, the inventors first performed RT-PCR analysis on mRNAs from E13.5, E15.5 and E17.5 fetal mouse pancreas. BMP 6 and BMP 7 and TGF- β 1 were expressed at each age, whereas BMP 5 was detected only at E15.5 and E17.5 and Activin A only at E17.5; BMP 2 and BMP 4 were not detected at any age.

BMP 6 and BMP 5, the BMPs expressed in E15.5 pancreas from which cells were isolated, synergized with laminin-1 to promote formation of cystic colonies (Figure 8). In the absence of laminin-1, BMP 6 or BMP 5 alone had no effect. Initially, some colonies appeared to be tubular by day 2 although most were cystic (Figure 8). At day 6, tubular colonies were hardly ever observed. Most of the colonies were 50-60 μ m in diameter although a few larger colonies of 100-200 μ m were also observed. Maximal stimulation of colony formation occurred at concentrations of 10 and 100 ng/ml BMP 6 and BMP 5, respectively; at higher concentrations, fewer colonies were observed (Figure 9).

In a number of diverse developmental settings the activity of BMPs is opposed by other members of the TGF- β superfamily, most notably TGF- β 1 itself and activins. Both TGF- β 1 and Activin A suppressed colony formation to levels below that observed with laminin-1 alone (Figure 10A). Furthermore, both molecules antagonized BMP 6-induced colony formation ($p < 0.01$) (Figure 10B). The dose-dependency of inhibition demonstrated that TGF- β 1 was 100-fold more potent than Activin A (Figure 10C). These results indicate that an interplay between TGF- β 1, Activin and BMP signaling may be critical for pancreas epithelial cell development.

Having established conditions that favor the formation of cystic colonies, the inventors next examined the nature of the colonies themselves. To determine if the cysts contained proliferating cells, BrdU labeling was performed during the last 16 hrs of culture. Up to 10 BrdU-positive cells per colony were detected (Figure 11), providing evidence that cellular proliferation contributed to colony formation.

Histology revealed the colonies to be duct-like in structure, containing various forms of epithelial cells surrounding a central lumen (Figures 12A-E). Some colonies were predominantly composed of columnar epithelial cells (Figure 12B), others of cuboidal cells (Figure 12C), squamous epithelial cells (Figure 12D) or a mixture of both columnar and squamous epithelial cells (Figure 12E). The majority of colonies were surrounded by a PAS-positive basement membrane (Figures 12F, 12G). Colony cells stained for E-cadherin, a specific epithelial cell marker involved in cell-cell interactions (Figures 12H, 12I) indicating that the colonies most likely originated from ductal progenitor epithelial cells.

Having identified cells in the colonies as epithelial in nature, the then sought to determine if the colonies contained differentiated cell types or only immature ductal epithelial cells. Insulin-positive cells were always observed in the areas where cystic epithelial cells appeared to be delaminating or segregating from the main body of the colony (Figures 13A-E). In addition, some individual insulin-positive cells were also observed between

colonies. Glucagon-positive cells were also present in colonies, but were less frequent than insulin-positive cells (Figure 13F) and somatostatin-positive cells were not detected. Although scattered α -amylase-positive cells were present, they were not associated with the colonies (Figures 13G, 13H).

5

This Example demonstrates an *in vitro* laminin-1 overlay system which allows single fetal pancreas progenitor cells to proliferate, differentiate and form cystic colonies containing hormone-positive cells. BMP 6 or BMP 5 were shown to synergize with laminin-1 to promote colony formation, whereas TGF- β 1, and to a markedly lesser extent Activin A, inhibited colony formation.

10

Pancreas duct cells and islets have previously been shown to be capable of forming cystic structures when cultured with ECM molecules. Adult human pancreas islet cells, for example, were found to “dedifferentiate” into ductal epithelial cells and form cystic structures when cultured in collagen I gel (Kerr-Conte *et al.*, 1996; Yuan *et al.*, 1996). These cells proliferated in a three dimensional culture, especially in presence of Matrigel (Kerr-Conte *et al.*, 1996). In addition, isolated human pancreas duct cells cultured with a high density Matrigel overlay were also shown to form ductal cysts (Bonner-Weir *et al.*, 2000). However, because Matrigel contains a number of ECM proteins and growth factors (McGuire and Seeds, 1989) it is difficult to identify the contribution made by individual molecules. The inventors circumvented this by using purified laminin-1 to establish a baseline from which to study the effect of specific extrinsic factors on pancreatic cell lineage development. Moreover, the endpoint of this culture system, the formation of cystic epithelial colonies containing differentiated endocrine cells, allowed the inventors to quantitate the effect of alterations in the culture parameters.

15

20

25

The findings herein suggest that TGF- β superfamily members play an important role in pancreas cell lineage development, reflected by the fact that BMP 6 or BMP 5 promote, and TGF- β or Activin A inhibit, colony formation. BMP 6 and BMP 5, as well as BMP 7, constitute the 60A subgroup of BMPs. RT-PCR revealed that all members of 60A subgroup of BMPs, and TGF- β 1 and Activin A, were expressed in the developing mouse

30

FOIA b 7 - D

pancreas. By immunocytochemistry, activin was detected in the E12.5 mouse pancreas epithelium and was restricted to developing islets at E18.5. The ability of fetal pancreas progenitor cells to proliferate, differentiate and form cystic epithelial colonies *in vitro* also indicates that the instant culture system partially recapitulates development *in vivo*.

5

In summary, the inventors demonstrate that specific BMPs promote growth and differentiation of fetal pancreas epithelial cells into cystic colonies containing insulin-positive β cells, an effect antagonized by two other members of the TGF- β superfamily, TGF- β 1 and Activin A. Characterization of extracellular factors that promote β -cell development has important implications for the treatment of type 1 diabetes.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

BIBLIOGRAPHY

Almeida *et al.* *Cell* **81**:1095-1104, 1995

Aono *et al.* *Biochem. Biophys. Res. Commun.* **210**:670-677, 1995

Bancroft, J D and Sevens, A, in *Theory and Practice of Histological Techniques* (Churchill Livingstone, Edinburgh), pp. 188-190

Bonner-Weir *et al.* *Proc. Natl. Acad. Sci. USA* **97**:7999-8004, 2000

Bottinger *et al.* *EMBO J.* **16**: 2621-33, 1997

Brown *et al.* *J. Cell. Sci.* **112**:209-216, 1999

Bucci *et al.* *Biol. Reprod.* **34**:195-206, 1986

Chan *et al.* *J. Cell. Biol.* **143**:2033-2044, 1998

Dudley *et al.* *Genes Dev.* **9**:2795-2807, 1995

Dudley *et al.* *Proc. Natl. Acad. Sci. USA* **92**:7686-7689, 1995

Durbeej *et al.* *J. Cell Biol.* **130**:79-91, 1995

Durbeej *et al.* *Curr. Opin. Cell. Biol.* **10**:549-601, 1995

Eklblom, P *Curr. Opin. Cell Biol.* **8**:700-706, 1996

Ervasti, J.M. and Campbell, K.P. *J. Cell. Biol.* **122**:809-823

1095-1104

Falk *et al. J. Cell. Sci.* **109**:2801-2810, 1996

Frade *et al. Exp. Cell Res.* **222**:140-149, 1996

Gao *et al. Diabetes* **45**:854-862, 1996

Georges *et al. Nature Genet.* **13**:370-373, 1996

Hebrok *et al. Genes Dev.* **12**: 1705-1713, 1998

Hogan, B.L *Curr. Opin. Genet. Dev.* **6**: 432-438, 1996

Jiang *et al. Diabetes* **48**:722-730, 1999

Jonsson *et al. Nature* **371**: 606-609, 1994

Katagiri *et al. J. Cell. Biol.* **127**:1755-1766, 1994 [erratum appears in *J. Cell. Biol.* **128**:713, 1995]

Kerr-Conte *et al. Diabetes* **45**: 1108-1114, 1996

Lelievre *et al. et al. Recent Prog. Horm. Res.* **54**:417-432, 1996

Luo *et al. Genes Dev.* **9**:2808-2820, 1995

Lyons *et al. Mech. Dev.* **50**: 71-83, 1995

McGuire, P G and Seeds, N W *J. Cell Biochem.* **40**:215-227, 1989

Offield *et al. Development* **122**: 983-995, 1996

2004-11-19 14:26:26

Pall *et al. J. Biol. Chem.* **271**:3817-3821, 1996

Powis *et al. Cancer Res.* **54**:2419-2423, 1994

Schuger *et al. Dev. Biol.* **179**:264-273, 1996

Slack, J.M.W. *Development* **121**:1569-1580, 1995

Sonnenberg *et al. J. Cell. Biol.* **110**:2145-2155, 1990

Streuli *et al. J. Cell Biol.* **129**:591-603, 1995

Uehara *et al. Mol. Cell. Biol.* **6**:2198-2206, 1986

Vlahos *et al. J. Biol. Chem.* **269**:5241-5248

Vukicevic *et al. Biochem. Biophys. Res. Commun.* **198**: 693-700, 1994

Weaver *et al. Development* **126**: 4005-4015, 1999

Winnier *et al. Genes Dev.* **9**:2015-2116, 1995

Wozney *et al. Science* **242**:1528-1534, 1988

Yamaoka *et al. J. Clin. Invest.* **102**: 294-301, 1998

Yuan *et al. Differentiation* **61**:67-75, 1996

Zhang and Bradley *Development* **122**:2977-2986, 1996

200507151546260